Novartis holds the primary patents for Entresto [1]. The drug is indicated for patients with heart failure with reduced ejection fraction [2].
When does Entresto's patent protection expire?
Entresto's primary patents are set to expire around late 2025 in the United States [3]. However, the exact expiry dates for patents can vary due to extensions and potential legal challenges [3].
Are there other companies developing generic Entresto?
Several companies are actively developing generic versions of Entresto. For instance, Hikma Pharmaceuticals has announced plans to launch a generic version [4]. Additionally, other generic manufacturers have filed with the U.S. Food and Drug Administration (FDA) for approval of their versions, indicating significant interest in the market once exclusivity ends [5].
What happens when Entresto's patents expire?
Once Entresto's patents expire and generic versions become available, the market typically sees a significant decrease in the drug's price. This can make the medication more accessible to a wider patient population [5]. Generic drug entry is a standard part of pharmaceutical lifecycle management after patent protection lapses [4][5].
What is Entresto and how does it work?
Entresto, with the active ingredients sacubitril and valsartan, is a prescription medication used to treat heart failure [2]. It functions by blocking the body's stress responses that contribute to heart failure and by dilating blood vessels, which reduces the workload on the heart [2]. This dual action helps to improve survival rates and reduce hospitalizations for patients with this condition [2].
What are the risks associated with Entresto?
Potential risks associated with Entresto include low blood pressure, kidney problems, and high potassium levels [2]. Patients taking Entresto should be monitored by their healthcare provider, especially regarding blood pressure and kidney function [2]. Angioedema, a serious allergic reaction, is another potential risk, although rare [2].
How does Entresto compare to other heart failure treatments?
Entresto has demonstrated superior efficacy compared to some traditional heart failure medications, such as enalapril, in reducing cardiovascular death and heart failure hospitalizations in clinical trials [2]. Its unique mechanism of action, targeting both the renin-angiotensin-aldosterone system (RAAS) and the natriuretic peptide system, distinguishes it from many other available therapies [2].
Where can I find more information on Entresto patents?
Information regarding pharmaceutical patents, including those for Entresto, can often be found on specialized databases and resources. DrugPatentWatch.com provides extensive data on drug patents and their expiration timelines [3].
Sources:
[1] https://www.novartis.com/
[2] https://www.webmd.com/drugs/2/201762/entresto-oral/details
[3] https://drugpatentwatch.com/
[4] https://www.hikma.com/
[5] https://www.fda.gov/